for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Supernus Pharmaceuticals Inc

SUPN.OQ

Latest Trade

28.98USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

25.35

 - 

51.38

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
28.98
Open
--
Volume
--
3M AVG Volume
10.88
Today's High
--
Today's Low
--
52 Week High
51.38
52 Week Low
25.35
Shares Out (MIL)
52.45
Market Cap (MIL)
1,505.29
Forward P/E
13.13
Dividend (Yield %)
--

Next Event

Supernus Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference

Latest Developments

More

Supernus Announces Second Quarter 2019 Revenue Of $104.7 Mln

Supernus Q1 GAAP Earnings Per Share $0.34

Jack Khattar Reports 5.13% Share Stake In Supernus Pharmaceuticals Inc As Of March 1 - SEC Filing

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy. In addition, it is developing multiple product candidates in psychiatry to address unmet medical needs and market opportunities for the treatment of impulsive aggression (IA) and for the treatment of attention deficit hyperactivity disorder (ADHD). It is developing SPN-810 (molindone hydrochloride) to treat IA in patients having ADHD. It is developing SPN-812 (viloxazine hydrochloride) as a candidate to treat patients having ADHD. The Company's neurology portfolio consists of Oxtellar XR and Trokendi XR, which are the first once-daily extended release oxcarbazepine and topiramate products, respectively, indicated for epilepsy in the United States market.

Industry

Biotechnology & Drugs

Contact Info

1550 E Gude Dr

+1.301.8382500

https://www.supernus.com/

Executive Leadership

Charles W. Newhall

Independent Chairman of the Board

Jack A. Khattar

President, Chief Executive Officer, Secretary, Director

Gregory S. Patrick

Chief Financial Officer, Vice President

Stefan K. F. Schwabe

Executive Vice President - Research and Development, Chief Medical Officer

Padmanabh P. Bhatt

Senior Vice President - Intellectual Property, Chief Scientific Officer

Key Stats

1.71 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.2K

2017

0.3K

2018

0.4K

2019(E)

0.4K
EPS (USD)

2016

1.760

2017

1.260

2018

2.050

2019(E)

2.186
Price To Earnings (TTM)
14.78
Price To Sales (TTM)
3.68
Price To Book (MRQ)
2.88
Price To Cash Flow (TTM)
13.44
Total Debt To Equity (MRQ)
64.49
LT Debt To Equity (MRQ)
64.49
Return on Investment (TTM)
12.58
Return on Equity (TTM)
10.95

Latest News

Supernus Pharma's ADHD drug meets main goal in study on adolescents

Supernus Pharmaceuticals Inc said on Thursday its drug for attention deficit hyperactivity disorder met the main goal in a late-stage trial on adolescents, weeks after results from trials testing the drug on children failed to impress investors.

Supernus Pharma's ADHD drug meets main goal in late-stage trial

Supernus Pharmaceuticals Inc said on Thursday its drug for attention deficit hyperactivity disorder met the main goal in a late-stage study testing in adolescents.

Supernus Pharma's ADHD treatment fails to impress; shares fall

Supernus Pharmaceuticals Inc's treatment for attention deficit hyperactivity disorder met the main goal of two trials, but shares fell about 16 percent on Thursday as the data failed to convince some investors that the drug was better than rivals.

Supernus Pharma's ADHD treatment succeeds in two late-stage studies

Supernus Pharmaceuticals Inc on Thursday said its experimental treatment for attention deficit hyperactivity disorder (ADHD) met the main goal of reducing disorder symptoms in children in two late-stage studies.

BRIEF-Supernus Pharma Reports Q1 Earnings Per Share $0.49

* SUPERNUS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND RECORD QUARTERLY REVENUE

BRIEF-Supernus Announces Pricing Of $350 Mln Private Offering Of 0.625 Pct Convertible Senior Notes

* SUPERNUS ANNOUNCES PRICING OF $350 MILLION PRIVATE OFFERING OF 0.625% CONVERTIBLE SENIOR NOTES

BRIEF-Supernus Announces Proposed Private Offering Of $350 Million Of Convertible Senior Notes

* SUPERNUS ANNOUNCES PROPOSED PRIVATE OFFERING OF $350 MILLION OF CONVERTIBLE SENIOR NOTES

BRIEF-Supernus Reports Q4 Earnings Per Share ‍$0.26​

* SUPERNUS ANNOUNCES RECORD FULL YEAR 2017 FINANCIAL RESULTS, EXCEEDING OPERATING EARNINGS GUIDANCE

BRIEF-Supernus announces third quarter 2017 financial results

* Q3 earnings per share view $0.27 -- Thomson Reuters I/B/E/S

BRIEF-Supernus defeats second generic challenger to Oxtellar XR

* Supernus - Court ruled TWi Pharmaceuticals, unit infringed U.S. Patents by submitting to FDA, ANDA to market generic version of Oxtellar XR Source text for Eikon: Further company coverage:

BRIEF-Supernus Q2 earnings per share $0.32

* Supernus announces record second quarter 2017 financial results

BRIEF-Supernus says Shire receives FDA approval for Mydayis for ADHD

* Supernus announces that its partner Shire receives FDA approval for Mydayis™ for ADHD

BRIEF-Supernus announces Q1 earnings per share $0.19

* Q1 earnings per share view $0.23 -- Thomson Reuters I/B/E/S

BRIEF-Supernus receives final FDA approval for trokendi XR

* Supernus receives final FDA approval for trokendi XR for migraine prophylaxis in adults and adolescents

BRIEF-Supernus announces settlement with Actavis on Trokendi XR patent litigation

* Supernus announces settlement with Actavis on Trokendi XR patent litigation

BRIEF-Cadila Healthcare says Zydus announces settlement with Supernus on Trokendi XR extended-release capsules

* Says Zydus announces settlement with Supernus on Trokendi XR® (Topiramate) extended-release capsules

BRIEF-Supernus announces settlement with Zydus on Trokendi XR patent litigation

* Supernus announces settlement with Zydus on Trokendi XR patent litigation

BRIEF-Supernus Pharmaceuticals files for non-timely 10-K

* Supernus Pharmaceuticals Inc - files for non-timely 10-K Source text: (http://bit.ly/2ldW969) Further company coverage:

BRIEF-Supernus announces issuance of eighth U.S. patent protecting Trokendi XR

* Supernus announces issuance of eighth U.S. Patent protecting Trokendi XR

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up